Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $118 on Alexion Pharmaceuticals; 2013 is Back-Weighted

Related ALXN
UPDATE: 8-K from Alexion Pharma Shows FDA Issued Form 483 at Aug. Inspection of Site, Does Not Expect Material Financial Effect Related to FDA Concern
Alexion Initiates Multinational Registration Trial of Eculizumab for Prevention of DGF after Kidney Transplantation

Stifel Nicolaus maintained Alexion Pharmaceuticals (NASDAQ: ALXN) with a Buy rating and lowered the price target from $125.00 to $118.00.

Stifel Nicolaus said, "Alexion posted FY12 top/bottom-line growth of >40% in the 5th consecutive year of Soliris commercialization – growth that appears readily achievable once again in FY13. While acknowledging the timing of European aHUS reimbursements and incremental data/news flow (mostly 2H13-weighted) is likely limiting the sense of urgency here, we remain hard-pressed to find a company with better fundamentals. We're taking our previously Street-high FY13 and forward-year estimates down marginally, reducing our target price to $118 (previously $125), and remaining Buy-rated."

Alexion Pharmaceuticals closed at $87.63 on Thursday.

Latest Ratings for ALXN

DateFirmActionFromTo
Sep 2014SunTrust Robinson HumphreyInitiates Coverage onBuy
Jul 2014Credit SuisseMaintainsNeutral
Jul 2014JP MorganMaintainsOverweight

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (ALXN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters